Abstract:Background: Combinations of Chinese patent medicines (CPM) with antidepressants (including selective serotonin reuptake inhibitors (SSRI), selective serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA), and noradrenergic and specific serotonergic antidepressants (NaSSA)) are frequently utilized for treating depression in adults. However, the efficacy and safety of these combination treatments remain to be established. Methods: Systematic search was conducted in seven electronic databases, regulatory websites and international registers of trials from 1994 to 2023 that included adult patients with depressive disorders who received CPM combined with antidepressants. The Multiple-Treatment Meta-Analysis (MTMA) was conducted using a random effects model with Stata/MP17 and R4.3.5 software. Primary outcomes were total efficacy rate, Hamilton Depression Scale (HAMD) score, and Treatment Emergency Symptom Scale (TESS) score. Secondary outcomes included brain-derived neurotrophic factor (BDNF) levels. Results: A total of 146 randomized controlled trials (13,754 participants: 6929 in intervention and 6825 in control groups) were included. For total effective rate, Multiple-Treatment Meta-Analysis results showed that the overall effect of combined intervention was better compared with antidepressants alone, where Jieyuanshenkeli (JYASKL) presented the optimal option for improving total efficacy (OR = 5.39, 95% CI [2.60, 11.18], SUCRA = 84.50%). In reduding the HAMD, Shuganjieyujiaonang (SGJYJN) was most likely to reduce the HAMD score (SMD = -2.20, 95% CI [-3.06, -1.33], SUCRA = 86.10%), Jieyuanshenkeli (JYASKL),Tianewangbuxindan (TWBXD), Shuyukeli (SYKL), Anshenbuxinwan (ASBXW) combination intervention did not appear to be statistically superior to antidepressants alone. In theTreatment Emergency Symptom Scale (TESS), Wulinjiaonang induced the most significant reduction in TESS score (SMD = -1.98, 95% CI [-3.59, -0.36], SUCRA = 90.40%). Tianmengjiaonang (TMJN) + Antidepressants(AD) (SUCRA = 88.30%) displayed the highest scores in increasing the levels of BDNF, although not statistically significant compared to Antidepressants(AD) alone (SMD = 1.23, 95% CI [0.90, 1.55]). Conclusion: Combinations of CPM and antidepressants showed superior efficacy over antidepressants alone. The optimal combinations were determined as Shuganjieyu Jiaonang (SGJYJN)/SSRIs and Jieyuanshenkeli (JYASKL)/SSRIs. In terms of safety, results showed that combination therapy did not show better TESS efficacy than antidepressants alone.Although some of the combination interventions were not superior than antidepressants alone in reducing HAMD scores,our findings provide a potentially significant alternative option for clinical complementary therapy. However, these results require further validation through larger sample sizes, multicenter randomized controlled trials, and real-world data.

Randomized,multicenter,double Blind Comparative Trial of Jin-yu-kang Capsule in the Treatment of Mild and Moderate Depression

Efficacy and safety of Jinyukang capsules in the treatment of mild and moderate depression

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Randomized, Double Blind, Placebo-Controlled Trial of Shuganjieyu Capsule in the Treatment of Mild or Moderate Depression

Efficacy and Safety of Anjiaxin Capsules in Treatment of Mild or Moderate Depression

Randomized, Double Blind, Double - Dummy, Multicenter, Parallel Controlled Clinical Trial of Kaiyuanshen in the Treatment of Depressive Disorder

Efficacy and Safety of Morinda Officinalis Oligose Capsule in the Treatment of Mild or Moderate Depression

Multi-center,randomized,and double-blind controlled clinical trial of duloxetine enteric capsule in treatment of depression

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John’s Wort for Major Depressive Disorder with Somatic Complaints

Clinical trial of bajitian oligosaccharide capsules in the treatment of depression

A Multicenter Clinical Trial of Wuling Capsule in Treatment of Functional Dyspepsia with Mild to Moderate Depression and Anxiety in Elderly

A Randomized Study on Comparing Effect and Safety of Wuling Capsule and Deanxit in Patients with Anxiety or Depression Status

Clinical trial of Wuling capsules in the treatment of Parkinson's disease with depression

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

Efficacy of Shuganjieyu Capsule for Treatment of Neurologic Disorders Combined with Depression: A Meta-Analysis

Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression

Antidepressant treatment of elderly heart failure patients complicated with depressed in traditional Chinese medicine and Western Medicine

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

A Randomized Double-Blind Controlled Clinical Trail of Venlafaxine Sustained Release Tablets Vs.sustained-Release Capsules in Treatment of Major Depression Disorder

Efficacy and safety of Chinese patent medicines combined with antidepressants for treatment of depression in adults: A multiple-treatment meta-analysis